Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Drug Pricing

March 19, 2018 | Daily News

The Trump administration plans to release a slate of proposals aimed at reducing prescription drug prices in about a month, President Trump and HHS Secretary Alex Azar said Monday (March 19).

March 16, 2018 | Daily News

A week after attacking drug-channel middle men, HHS Secretary Alex Azar touted cuts to hospitals’ Medicare reimbursement for 340B drugs as an example of transparency and fairness in drug pricing at a community health centers conference on Friday (March 16).

March 15, 2018 | Daily News

Safety-net hospitals and drug makers each said Thursday (March 15) that they support transparency, but such requirements need to be applied to all sectors that profit from drug sales.

March 14, 2018 | Daily News

Academics who have backed changing the 340B program are calling for tweaks to 340B-overhaul bills, the 340B PAUSE and 340B HELP Acts, to better account for safety-net services.

March 13, 2018 | Daily News

Brand drug lobbyists say there is a decent chance Congress will lower drug companies’ share of Medicare Part D donut-hole costs by 5 percent to 6 percent as lawmakers could provide that much relief without increasing the deficit due to an updated estimate by the Congressional Budget Office, though drug makers are unlikely to get more than that because lawmakers don’t want to negotiate offsets.

March 09, 2018 | Daily News

Pew Charitable Trusts reports that rescinding protected drug classes likely would not save that much money because generic competition is strong in those drug classes, plans already can restrict coverage using other tools and Medicare requirements that are separate from protected class status might prevent plans from excluding drugs anyway.

March 08, 2018 | Daily News

The Senate health committee will hold a hearing on the controversial 340B drug discount program on Thursday (March 15), and while the hearing notice says lawmakers will hear different perspectives on the program, it doesn't specify who will testify.

March 07, 2018 | Daily News

FDA Commissioner Scott Gottlieb said Wednesday (March 7) that the “rigged” rebate system discourages the development of biosimilars, marking the third straight day of negative press for pharmacy benefit managers.

March 07, 2018 | Daily News

FDA Commissioner Scott Gottlieb said Wednesday (March 7) that the agency is working with HHS Secretary Alex Azar on policies that will help bring more biosimilars to the market, including providing regulatory clarity by integrating policy and review functions; offering tools to help sponsors rely on smaller, targeted trials and develop interchangeable products; countering “misperceptions” about biosimilar safety; and harmonizing development with overseas regulatory partners.

March 06, 2018 | Daily News

HHS Secretary Alex Azar and brand drug companies praised UnitedHealthcare for sharing rebates with its customers, and the Pharmaceutical Research and Manufacturers of America says Medicare Part D should adopt the health insurance company’s policy.

March 05, 2018 | Daily News

Nearly all published studies evaluating switching between a biologic and a biosimilar show no differences in immunogenicity, safety or efficacy, according to a newly published literature review from top experts at Sandoz, Novartis and Avalere Health.

March 05, 2018 | Daily News

The Patent Trial and Appeal Board's move late last month to shoot down a closely followed attempt by the Saint Regis Mohawk Tribe to assert sovereign immunity in a bid to keep the Restasis dry eye drug patents it acquired from Allergan out of the inter partes review process has sparked new debate over the board's authority to make such a determination and predictions the issue will ultimately land at the U.S. Supreme Court.

March 02, 2018 | Daily News

Congressional Medicaid advisers recommended Thursday (March 1) that Congress give CMS the power to fine drug makers for classifying brand drugs as generics to evade Medicaid drug rebates.

March 01, 2018 | Daily News

Sen. Charles Grassley (R-IA) on Tuesday (Feb. 27) introduced legislation to make hospitals report on savings they get from the 340B program, but 340B hospitals say the bill would take savings out of context, and one lobbyist says the legislation could be a stepping stone toward larger 340B reforms.

March 01, 2018 | Daily News

In preparation for writing price-transparency legislation, a bipartisan group of senators is seeking advice on making information on prices for health care services and products available to the public and holding providers and companies accountable for those prices. The lawmakers request feedback from several trade groups, but a press release on the request doesn’t list drug makers or drug-distribution middlemen among the recipients, even though drugs typically are a target of price-transparency proposals.

February 28, 2018 | Daily News

Sponsors of the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act are pushing for the bill to be included in the omnibus spending legislation, which must pass by March 23 to avoid a government shutdown.

February 23, 2018 | Daily News

The Center for American Progress suggests Medicare negotiate prices for retail drugs, consumer medical equipment, and medical devices used in surgeries and medical procedures.

February 22, 2018 | Daily News

Industry challenges to state drug pricing laws in Nevada and Maryland are unlikely to succeed and that bodes well for states that want to enact similar laws, argue two professors who are frequently critical of the drug industry.

February 16, 2018 | Daily News

House and Senate lawmakers worry about the effects of pharmacy benefit manager consolidation, and nominees to the Federal Trade Commission said they expect FTC to review past PBM mergers.

February 14, 2018 | Daily News

Patients for Biologics Safety & Access is calling on FDA to rework portions of its newly released web page meant to educate prescribers about biosimilars, with the group suggesting changes aimed at downplaying the agency's safety assurances.

Pages